Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy
Year: 2020
Type: article
Source: Blood
Authors: Jonathan L. Kaufman, Jacob P. Laubach, Douglas Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca W. Silbermann, Luciano J. Costa, Larry D. Anderson, Nitya Nathwani, Nina Shah, Yvonne A. Efebera, Sara A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Yana Lutska, Padma Bobba, Huiling Pei, Jon Ukropec, Jessica Vermeulen, Thomas S. Lin, Paul G. Richardson, Peter M. Voorhees
Institutions: Emory University, Winship Cancer Institute, Dana-Farber Cancer Institute, Huntsman Cancer Institute, University of North Carolina at Chapel Hill, Wake Forest University Health Sciences, Wake Forest University, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, OHSU Knight Cancer Institute, University of Alabama at Birmingham, Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, City Of Hope National Medical Center, City of Hope, University of California, San Francisco, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, University of Nebraska Medical Center, University of California San Diego, Moores Cancer Center, University of Chicago Medical Center, Washington University in St. Louis, The University of Texas MD Anderson Cancer Center, Moffitt Cancer Center, University of Washington, Janssen Scientific Affairs (United States), Janssen (Netherlands), Levine Cancer Institute
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3097144589